recent news
- X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
- X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility
- X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates